iBio’s Virus-Like Particle (VLP) Platform

vlp_442x322@2x

The iBio VLP platform is based on the production of non-enveloped virus-like particles composed of viral core proteins that self-assemble into spherical particles. This type of VLP, with one major protein component, is:

  • Simple by design
  • Amenable to production scale-up
  • Highly flexible for antigen display
  • Adaptable to outbreaks of new viral strains and deployable with rapid scale-up and manufacturing

ADVANTAGES OF IBIO’S VLP APPROACH:

iBio VLP platform (non-enveloped VLP)

  • High yield
  • Simpler
  • Low impurity content

Enveloped VLP

  • Low yield
  • Complex and potentially inconsistent structure
  • Higher impurity risk (of host cell proteins)

PLANTS ARE IDEAL VLP BIOREACTORS

  • Plants have sophisticated eukaryote protein production machinery that also supports the amplification of numerous plant-specific viruses.
  • Both VLPs and natural plant viruses are non-enveloped particles, composed of simple proteins, that can be produced in complex forms of various shapes (spheres for VLPs).
  • Plant cells are very efficient producers of proteinaceous viruses and VLPs.

IBIO’S FastPharming  VLP PRODUCTION CAPACITY

  • Consistently high-quality nanoparticles produced to date
  • Arguably superior to Sf9, HEK293, and other expression systems due to slower, precise assembly
  • Scalable

ADVANTAGES OF VLPs

VLP-based vaccines interact with immune cells differently than soluble antigens. The size and repetitive antigen presentation of VLPs have been demonstrated to trigger both humoral and cellular responses, but more importantly to generate memory cells and long-lasting plasma cells, potentially providing years of protection without compromising safety.1,2    

  • Maintain their viral structural characteristics (size and geometry) but are not infectious
  • Expressed in recombinant systems
  • Production process uses conventional methods that are well understood by regulators
  • Promote protective neutralizing antibodies
    • Effective antiviral response
    • Strong antibody titers at low dose
    • Activate B cells for antibody production
  • Promote B cell memory
    • Induction of long-lived plasma cells (LLPCs), which can persist for a decade

 

 

iBio is currently developing IBIO-200, a VLP-based vaccine candidate in which a SARS-CoV-2 antigen is fused to a self-assembling protein partner and displayed in a repetitive structure and geometry, decorated with oligomannose molecules to resemble the structure of a naturally occurring virus.

References:

  1. Schmidt, M.E. and S.M. Varga. (2018). “The CD8 T Cell Response to Respiratory Virus Infections. Front Immunol. 9: 678
  2. Brown M. et al. (2012) Virus-like particles induce robust human T-helper cell responses. J. Immunol. 42(2)330–340